SHANGHAI--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today held a traditional groundbreaking ceremony to celebrate the establishment of the joint global manufacturing, supply and R&D center in Suzhou, China. Construction. The new plant will focus on the development and production of high-quality vaccines for pigs, cattle, fish and companion animals to help prevent the epidemic strains in China. Zoetis also opened a temporary R&D facility near Suzhou. The company's PHARMAQ business will begin to develop vaccines for China's farmed fish industry; a multinational company will set up the first R&D center focused on aquaculture in mainland China. These activities affirm the company's continued investment and commitment to China's innovation, manufacturing excellence and growth.
"Suo Teng has a deep understanding of the animal health challenges that Chinese animal husbandry and veterinary professionals face every day," said Mike Wang, Senior Vice President of Suo Teng Greater China. "With this new vaccine innovation center and Suzhou's expanded production capacity, as well as a well-trained on-site representative team, we are able to help Chinese livestock farmers respond to the increasing demand for safe and sufficient pork and milk supplies. Heyu. We can support veterinarians because they work hard to help pets live longer and healthier."
Shuo Teng is a leading multinational animal health company in China, with revenue of US$174 million in China in 2017. Shuo Teng started its business in China in 1995 and has approximately 600 employees and a commercial headquarters in Shanghai. The product portfolio includes more than 80 product lines in five product categories including vaccines, parasiticides, anti-infectives, medicinal feed additives and other medical products, serving the six core animal species-pigs, dairy cows, poultry, fish, Dogs and cats. In terms of annual revenue, China is the fifth largest market in the world.
Expanding in China and for China's innovation
The planned vaccine research and development (R&D) center in Suzhou will expand and strengthen the ongoing innovations of the Beijing Shuoteng R&D laboratory, which opened in 2015.
"The future work of our scientists in Suzhou will help accelerate the development of high-quality vaccines that meet the animal health needs of the Chinese market. This will allow us to expand from vaccines that initially focused on pigs to vaccines for cattle and fish as for companion animals," Shuo Teng Said Dr. Catherine Knupp, Executive Vice President and President of R&D. "Sotron scientists from our Beijing laboratory and our global R&D network will work with the Suzhou-based R&D team to help accelerate the introduction of Sotron's technology and processes to develop high-quality vaccines and drugs for China." China Animal Vaccines in 2017 The market value exceeds US$1.8 billion1.
In the start-up R&D laboratory in Suzhou, PHARMAQ scientists will mainly focus on understanding the disease threats in China's aquaculture sector. These expertise will become the basis for the development of safe and effective vaccines for the Chinese aquaculture industry. Vaccines are expected to become an important health management tool for the Chinese aquaculture industry, helping to control the diseases that pose the greatest threat to the industry. China is the world's largest aquaculture country. In 2016, the production of farmed fish was approximately 50 million tons2, accounting for 63% of global production2. Increasing dependence on vaccines for disease control may help reduce the use of antibiotics to treat bacterial diseases in farmed fish. Once Zoetis completes the construction of the new R&D and manufacturing joint facility, R&D operations will be transferred to the new facility.
Improve China's manufacturing capabilities and capabilities
"We at Soton regard China as the global center of high-quality manufacturing and innovation," said Roman Trawicki, Executive Vice President and President of Global Manufacturing and Supply of Soton, who presided over the groundbreaking ceremony. "The completion of the new vaccine production facility in Suzhou will establish a center of excellence that specializes in producing high-quality vaccines that meet the needs of the Chinese market. It will expand our manufacturing capabilities and capabilities in China."
The new innovation and manufacturing facility in Suzhou will include 43,000 square meters of vaccine manufacturing operations and laboratory space. Zoetis expects to complete the construction and Good Manufacturing Practice certification of the Ministry of Agriculture of China by 2021.
The base will use the most advanced virus and bacterial vaccine manufacturing technology, and will include pilot-scale manufacturing for the development of new vaccine products. Zoetis expects to add approximately 100 new R&D and manufacturing positions at the plant in the next two years.
The new plant will become the company's second vaccine production base in China. In 2017, Shuo Teng became the sole owner of its original joint venture vaccine production base. Since 2011, the company has produced vaccines for pigs suitable for the Chinese market. Innovative products developed there include the special vaccine RuilananTM launched in 2013 to help control the highly pathogenic porcine reproductive and respiratory syndrome (PRRS) discovered in China. In 2016, Shuo Teng also launched Relan Wen™, the first approved combined vaccine in China to help protect pigs from the local epidemic of swine fever (CSF) and porcine reproductive and respiratory syndrome (PRRS). Infringe.
The new plant will also become the company's second global manufacturing and supply plant in Suzhou. Zoetis opened a state-of-the-art factory there in 2015, where it produces medicated feed additive products as well as water-soluble and pre-mixed products used to help raise healthy pigs, cattle and poultry. Products include Linco-Spectin®, Lincomix®, Tilmicosin® and COT (Check-O-Tox®).
About China's animal health market
China is the world's second largest animal health market, valued at approximately US$4.3 billion in 2017, and is expected to grow at a compound annual growth rate of 7% to 10%3. Vaccines remain the most important growth driver. China is a world leader in pork production and has the largest pig herd in the world, with farmers raising 700 million pigs every year1. China’s pet ownership and healthcare expenditures are increasing. In 2017, spending on pet medicines and vaccines was approximately US$300 million1. The animal health industry is committed to supporting the work of farmers, providing safe and healthy food supplies from healthy farm animals, and helping pets live longer and healthier.
Zoetis is a leading animal health company dedicated to supporting its customers and their businesses. With more than 60 years of experience in the field of animal health, Shuo Teng discovers, develops, manufactures and sells veterinary vaccines and drugs, supplemented by diagnostic products, genetic testing, biological equipment and a series of services. Zoetis serves veterinarians, livestock producers, and people who raise and care for farms and companion animals, and its products are sold in more than 100 countries. In 2017, the company had approximately 9,000 employees and annual revenue of $5.3 billion. For more information, please visit www.zoetis.com
1 Vetnosis 2017 STORM report 2 OECD-FAO 2017-2026 Agricultural Outlook Database; https://read.oecd-ilibrary.org/agriculture-and-food/oecd-fao-agriculture-outlook-2017-2026/fish-and -seafood_agr_outlook-2017-12-en#; visit 04-03-18 3 Zoetis internal estimates
Media Zoetis Inc. Yu Fang, +86 21 22610265 (O) fang.yu@zoetis.com or Elinore White, 973-443-2835 (O) elinore.y.white@zoetis.com
Zoetis announced plans to expand its animal vaccine research and production in Suzhou, China.
Media Zoetis Inc. Yu Fang, +86 21 22610265 (O) fang.yu@zoetis.com or Elinore White, 973-443-2835 (O) elinore.y.white@zoetis.com